Saturday 17 October 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 58.7% and free cash flow fell 64.8%, each against the same quarter a year earlier.
27.57
2.00
−6.76%
Follow RAPP
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
Current Ratio |
26.17 | 35.34 | 17.14 | 18.80 |
Net Debt/EBITDA |
3.91 | 3.57 | 4.08 | 3.01 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.78 | 0.83 | 0.78 | 0.30 |
Capex/Depreciation |
1.63 | 1.01 | (44.22) | (352.27) |
Interest Coverage |
— | — | — | (36.38) |
| (28.22%) | (55.97%) | 194.90% | 0.00% | |
| (26.95%) | (33.30%) | (37.20%) | 0.00% | |
ROIC |
0.00% | (123,593.75%) | 0.00% | 0.00% |
Return on Tangible Assets |
(23.11%) | (25.71%) | (24.16%) | (35.58%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(2.26) | (3.24) | (19.13) | (10.97) |
Cash per Share |
12.60 | 14.73 | 97.98 | 40.10 |
Shareholders Equity per Share |
12.45 | 14.73 | 93.59 | 25.10 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
12.45 | 14.73 | 93.59 | 25.10 |
Free Cash Flow |
(88.09) | (67.23) | (28.82) | (8.53) |
Working Capital |
479.51 | 301.04 | 142.07 | 29.61 |
Capital Expenditures |
(0.62) | (2.40) | (1.64) | (5.28) |
Net Current Asset Value |
470.78 | 300.30 | 136.39 | 19.17 |
| Other line items | ||||
Quick Ratio |
25.76 | 34.83 | 16.76 | 18.74 |
Depreciation/Fixed assets |
(0.13) | (0.67) | 0.02 | 0.04 |
Cash ROIC |
(9.03%) | (11.01%) | (9.99%) | (16.83%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(2.25) | (3.13) | (18.05) | (4.17) |
Capex per Share |
(0.02) | (0.12) | (1.09) | (6.80) |
Average Payables |
3.07 | 2.23 | 1.98 | — |
Average Assets |
413.68 | 235.18 | 93.51 | — |
Average Common Equity |
395.04 | 139.90 | (17.85) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates